Lilly and Resilience Commit $750 Million to U.S. Drug Manufacturing Expansion
Eli Lilly and contract manufacturer Resilience will channel $750 million into expanding U.S. pharmaceutical manufacturing capacity, a move aimed at strengthening the domestic medicine supply chain, creating 400 skilled positions in the Cincinnati area and bringing Lilly's KwikPen injectable into local production.